Can Tango Therapeutics cover its short-term obligations?

Its current ratio is 27.38 — current assets exceed current liabilities.

Where does Tango Therapeutics's balance sheet data come from?

Every line is extracted from Tango Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Tango Therapeutics TNGX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$159.97M+162%	$112.28M+61.5%	$60.91M+9.3%	$41.84M-22.7%	$61M-4.3%
Short-term investments	$222.01M+40.3%	$230.86M+22.5%	$94.47M-60.7%	$141.51M-47.7%	$158.29M-44.0%
Restricted cash	$0-100%	$428K-52.4%	$428K-83.3%	$428K-83.3%	$428K-83.3%
Prepaid expenses and other current assets	$12.49M+60.6%	$10.19M+20.9%	$10.54M+39.8%	$8.89M+41.1%	$7.78M-7.8%
Total current assets	$392.33M+74.4%	$353.76M+32.8%	$163.78M-45.6%	$190.1M-42.1%	$224.93M-36.1%
Property and equipment, net	$6.38M-15.4%	$6.87M-15.2%	$7.35M-14.5%	$7.79M-14.4%	$7.54M-20.8%
Accumulated depreciation	$10.94M+21.8%	$10.54M+26.0%	$10.06M+29.9%	$9.61M+35.0%	$8.99M+35.9%
Operating lease right-of-use assets	$34.65M-12.7%	$35.62M-9.8%	$36.58M-9.5%	$37.56M-9.2%	$39.7M-5.7%
Other non-current assets	$293K+29,200%	$303K+7,475%	$290K+2,131%	$310K+3,000%	$1K-90.9%
Total assets	$435.79M+58.9%	$398.69M+26.0%	$210.14M-40.4%	$237.89M-37.6%	$274.31M-32.5%
Accrued expenses	$3.24M+1.9%	$9.05M+1.1%	$6.48M-0.4%	$5.6M+3.2%	$3.18M+11.3%
Operating lease liabilities, current	$2.83M+0.3%	$2.74M+11.6%	$3.1M+8.3%	$2.53M+7.2%	$2.82M+36.7%
Accrued interest	$1.2M+33.3%	$1M-28.6%	$700K-41.7%	$700K-50.0%	$900K-35.7%
Total current liabilities	$14.33M-60.1%	$21.68M-43.2%	$18.44M-50.9%	$40.03M-8.8%	$35.92M-16.1%
Operating lease liabilities, non-current	$29.96M-12.2%	$30.83M-9.4%	$31.66M-8.9%	$32.47M-8.5%	$34.12M-5.7%
Operating Lease Liabilities (Total)	——	——	——	——	——
Total liabilities	$44.29M-58.8%	$52.51M-55.1%	$50.11M-59.3%	$102.94M-23.1%	$107.55M-24.1%
Common stock	400M+100%	200M+185,085%	400M+100%	400M+100%	200M0.0%
Additional paid-in capital	$1.04B+46.9%	$948.97M+35.4%	$724.2M+4.6%	$715.04M+4.7%	$707.89M+5.1%
Retained earnings	-$648.67M-19.8%	-$603.15M-20.3%	-$564.4M-21.7%	-$580.29M-33.5%	-$541.43M-32.3%
Accumulated other comprehensive income (loss)	-$115K-159%	$224K-33.3%	$121K-83.9%	$94K+128%	$194K+175%
Total stockholders' equity	$391.51M+135%	$346.18M+73.5%	$160.03M-30.2%	$134.95M-45.5%	$166.76M-36.9%
Total liabilities and stockholders' equity	$435.79M+58.9%	$398.69M+26.0%	$210.14M-40.4%	$237.89M-37.6%	$274.31M-32.5%
Available-for-Sale Debt Securities - Amortized Cost	$222.13M+40.5%	$230.64M+22.6%	$94.35M-60.6%	$141.42M-47.8%	$158.1M-44.1%
Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months)	——	——	——	——	——
AFS and Trading Securities - Unrealized Loss Position (>=12 Months)	——	——	——	——	——
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	——	——	$10.02M-79.9%	$69.91M-66.0%	$56.85M-68.1%
Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months)	——	——	$10.02M-79.9%	$69.91M-66.0%	$56.85M-68.1%
Available-for-Sale Debt Securities - Unrealized Loss Position	——	——	$1K-93.3%	$21K-94.2%	$27K-91.3%
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value	——	——	——	——	——
AFS and Trading Securities - Unrealized Loss Position Fair Value	——	——	$10.02M-79.9%	$69.91M-66.8%	$56.85M-70.3%
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	——	——	$10.02M-79.9%	$69.91M-66.0%	$56.85M-68.1%
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)	$159.97M+162%	$114.85M+59.3%	$60.91M+9.3%	$41.84M-22.7%	$61M-4.3%
Cash, Cash Equivalents, and Marketable Securities	——	——	$10.02M-79.9%	$69.91M-66.8%	$56.85M-70.3%
Available For Sale Securities Debt Securities Current	$222.01M+40.3%	$230.86M+22.5%	$94.47M-60.7%	$141.51M-47.7%	$158.29M-44.0%
Cash Cash Equivalents And Short Term Investments	——	——	——	——	——
Short- term Investments	$222.01M+40.3%	$230.86M+22.5%	$94.47M-60.7%	$141.51M-47.7%	$158.29M-44.0%
Deferred Tax Assets and Other Non-Current Assets	$293K+29,200%	$303K+7,475%	$290K+2,131%	$310K+3,000%	$1K-90.9%
Investments - Amortized Cost Basis	$222.13M+40.5%	$230.64M+22.6%	$94.35M-60.6%	$141.42M-47.8%	$158.1M-44.1%
Net Investment in Lease	$34.65M-12.7%	$35.62M-9.8%	$36.58M-9.5%	$37.56M-9.2%	$39.7M-5.7%
Operating lease right-of-use assets	$34.65M-12.7%	$35.62M-9.8%	$36.58M-9.5%	$37.56M-9.2%	$39.7M-5.7%
Other non-current assets	$293K+29,200%	$303K+7,475%	$290K+2,131%	$310K+3,000%	$1K-90.9%
Property, plant and equipment at cost	$17.32M+4.8%	$17.41M+5.7%	$17.41M+6.6%	$17.4M+7.3%	$16.52M+2.4%
Operating Lease Right-of-Use Assets in Other Assets	$34.65M-12.7%	$35.62M-9.8%	$36.58M-9.5%	$37.56M-9.2%	$39.7M-5.7%
Software and Technology Licenses, Net	$293K+29,200%	$303K+7,475%	$290K+2,131%	$310K+3,000%	$1K-90.9%
Accrued Manufacturing Costs	$3.24M+1.9%	$9.05M+1.1%	$6.48M-0.4%	$5.6M+3.2%	$3.18M+11.3%
Accrued Expenses And Other Current Liabilities	$9.07M-12.6%	$17.76M+7.6%	$13.11M-12.6%	$11.51M-31.4%	$10.37M-24.6%
Compensation and benefits	$3.24M+1.9%	$9.05M+1.1%	$6.48M-0.4%	$5.6M+3.2%	$3.18M+11.3%
Total debt	$32.79M-11.3%	$33.57M-8.0%	$34.76M-7.6%	$35.01M-7.5%	$36.95M-3.4%
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Accumulated Loss	——	——	——	——	——
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	144.2M+33.4%	135.9M+26.2%	111.6M+3.9%	110.9M+3.6%	108.1M+1.3%
Common Stock Shares Outstanding	$313.61M—	$60.72M+2,715%	$59.82M+82.5%	$20.8M-51.5%	$0-100%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$144K+33.3%	$136K+25.9%	$112K+4.7%	$111K+3.7%	$108K+0.9%
Investments - Gross Unrealized Losses	——	——	$10.02M-79.9%	$69.91M-66.8%	$56.85M-70.3%
Number of Exercisable Options	——	——	——	——	——
Share-Based Payment Award Options Outstanding - Number	24.1M+1.2%	20.5M+4.3%	22.6M+13.9%	23.7M+15.8%	23.8M+15.6%
Unrealized Gains on Investments	$19K-91.4%	$224K-40.3%	$122K-84.1%	$115K+283%	$221K+317%
Unrealized Losses on Investments (Before Tax)	$134K+396%	$0-100%	$1K-93.3%	$21K-94.2%	$27K-91.3%
Weighted Average Exercise Price of Outstanding Options	$7.91+20.4%	$6.53-11.9%	$6.59-11.4%	$6.52-12.7%	$6.57-12.0%
Cumulative Cost Basis	$222.13M+40.5%	$230.64M+22.6%	$94.35M-60.6%	$141.42M-47.8%	$158.1M-44.1%
Accrued Research And Development Costs Current	$4.27M-18.1%	$7.42M+27.8%	$4.91M-14.7%	$3.92M-60.2%	$5.22M-41.5%
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$134K+396%	$0-100%	$1K-93.3%	$21K-94.2%	$27K-91.3%
Gross Unrealized Gains	$19K-91.4%	$224K-40.3%	$122K-84.1%	$115K+283%	$221K+317%
Total	$222.13M+40.5%	$230.64M+22.6%	$94.35M-60.6%	$141.42M-47.8%	$158.1M-44.1%
Cash Cash Equivalents And Marketable Securities	——	——	——	——	——
Cash and cash equivalents, end of period	$159.97M+162%	$114.85M+59.3%	$60.91M+9.3%	$41.84M-22.7%	$61M-4.3%
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$400M+100%	$200M0.0%	$400M+100%	$400M+100%	$200M0.0%
Common stock, shares issued (in shares)	$144.16M+33.4%	$135.94M+26.2%	$111.57M+3.9%	$110.87M+3.6%	$108.11M+1.3%
Common Stock, Shares, Outstanding	$144.16M+33.4%	$135.94M+26.2%	$111.57M+3.9%	$110.87M+3.6%	$108.11M+1.3%
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	——	——	——	——	——
Less than 12 months	——	——	$10.02M-79.9%	$69.91M-66.0%	$56.85M-68.1%
12 months or more	——	——	——	——	——
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	——	——	$1K-93.3%	$21K-94.0%	$27K-89.7%
Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss	——	——	$1K-93.3%	$21K-94.2%	$27K-91.3%
Debt Securities, Available-for-Sale, Unrealized Loss Position	——	——	$10.02M-79.9%	$69.91M-66.8%	$56.85M-70.3%
Fair Value Asset Level1To Level2Transfer Amount	——	——	——	——	——
Fair Value Asset Level2To Level1Transfer Amount	——	——	——	——	——
Fair Value Liabilities Level1To Level2Transfer Amounts	——	——	——	——	——
Fair Value Liabilities Level2To Level1Transfer Amounts	——	——	——	——	——
Other accrued liabilities	$1.56M-21.2%	$1.29M-25.7%	$1.73M-37.0%	$2M+31.8%	$1.98M-0.5%
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$24.1M+1.2%	$20.47M+4.3%	$22.58M+13.9%	$23.73M+15.8%	$23.81M+15.6%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$7.91+20.4%	$6.53-11.9%	$6.59-11.4%	$6.52-12.7%	$6.57-12.0%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	$313.61M—	$60.72M+2,715%	$59.82M+82.5%	$20.8M-51.5%	$0-100%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value	——	——	——	——	——
Temporary Equity Par Or Stated Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Temporary Equity Shares Authorized	10M0.0%	10M0.0%	10M0.0%	10M0.0%	10M0.0%
Temporary Equity Shares Issued	0—	0—	0—	0—	0—
Temporary Equity Shares Outstanding	0—	0—	0—	0—	0—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Tango Therapeutics cover its short-term obligations?: Its current ratio is 27.38 — current assets exceed current liabilities.
Where does Tango Therapeutics's balance sheet data come from?: Every line is extracted from Tango Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.